Allogene Therapeutics (ALLO) News Today → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free ALLO Stock Alerts $2.76 -0.10 (-3.50%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAllogene Therapeutics earnings: here's what Wall Street expectsmarkets.businessinsider.com - May 12 at 10:10 AMAllogene Therapeutics (ALLO) to Release Quarterly Earnings on Mondayamericanbankingnews.com - May 11 at 1:44 AMAllogene Therapeutics (ALLO) Set to Announce Quarterly Earnings on Mondaymarketbeat.com - May 7 at 1:26 PMAllogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Rating of "Moderate Buy" from Brokeragesamericanbankingnews.com - May 7 at 1:44 AMAllogene Therapeutics to Report First Quarter Financial Results and Provide Business Updateglobenewswire.com - May 6 at 8:30 AMALLO Allogene Therapeutics, Inc.seekingalpha.com - May 2 at 6:01 PMAllogene Therapeutics (NASDAQ:ALLO) Stock Price Up 6.6%marketbeat.com - April 29 at 1:56 PMAllogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinomaglobenewswire.com - April 26 at 8:30 AMAllogene Therapeutics (NASDAQ:ALLO) Shares Down 3.6% marketbeat.com - April 24 at 3:37 PM517,581 Shares in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Bought by Cerity Partners LLCmarketbeat.com - April 20 at 5:32 AMTo The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation - Allogene Therapeutics (NASDAQ:ALLO), ARK Innovation ETF (ARCA:ARKK)benzinga.com - April 18 at 2:29 PMAllogene Therapeutics (NASDAQ:ALLO) Stock Price Down 6.1%marketbeat.com - April 15 at 5:31 PMVanguard Group Inc. Purchases 3,086,311 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)marketbeat.com - April 12 at 4:08 AMAllogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Rating of "Moderate Buy" by Brokeragesmarketbeat.com - April 12 at 2:33 AM3 Meme Stocks to Sell and Replace With Meme Coinsinvestorplace.com - April 11 at 2:45 PMAllogene Therapeutics (NASDAQ:ALLO) Shares Up 2.2%marketbeat.com - April 10 at 2:51 PMAllogene Therapeutics Announces Q2 Investor Conference Participationglobenewswire.com - April 9 at 8:30 AMAllogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upsideseekingalpha.com - April 1 at 2:41 AMZacks Research Weighs in on Allogene Therapeutics, Inc.'s FY2026 Earnings (NASDAQ:ALLO)marketbeat.com - March 31 at 1:49 AMAllogene Therapeutics (NASDAQ:ALLO) Trading 9% Higher marketbeat.com - March 27 at 4:44 PMStifel Nicolaus Sticks to Their Hold Rating for Allogene Therapeutics (ALLO)markets.businessinsider.com - March 20 at 5:19 AMAllogene Therapeutics Poised for Growth: A Strong Buy Rating Amidst Innovative Trials and Strategic Advancementsmarkets.businessinsider.com - March 19 at 9:16 AMAllogene Therapeutics (NASDAQ:ALLO) Stock Rating Reaffirmed by HC Wainwrightmarketbeat.com - March 19 at 8:34 AMAnalysts Offer Insights on Healthcare Companies: Black Diamond Therapeutics (BDTX) and I-MAB (IMAB)markets.businessinsider.com - March 18 at 11:13 PMRoyal Bank of Canada Reiterates Outperform Rating for Allogene Therapeutics (NASDAQ:ALLO)marketbeat.com - March 18 at 3:10 PMAllogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokeragesmarketbeat.com - March 18 at 2:39 AMAllogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 16 at 6:34 PMAllogene Therapeutics, Inc.: Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updatefinanznachrichten.de - March 15 at 4:16 PMAllogene Therapeutics: Redefining LBCL Treatment with Innovative ALPHA3 Trial and Promising Cema-cel Therapymarkets.businessinsider.com - March 15 at 4:16 PMAllogene Therapeutics: Advancing Clinical Studies and Promising Treatment Differentiation Set Stage for Stock Value Growthmarkets.businessinsider.com - March 15 at 11:12 AMAllogene Therapeutics (NASDAQ:ALLO) Stock Price Up 3.8% on Better-Than-Expected Earningsmarketbeat.com - March 15 at 10:25 AMALLO Stock Earnings: Allogene Therapeutics Misses EPS, Beats Revenue for Q4 2023investorplace.com - March 14 at 10:04 PMAllogene Therapeutics files for $500M mixed shelfmsn.com - March 14 at 9:00 PMAllogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updateglobenewswire.com - March 14 at 4:05 PMAllogene Therapeutics (NASDAQ:ALLO) Shares Down 8.2% marketbeat.com - March 14 at 12:47 PMAllogene Therapeutics Q4 2023 Earnings Previewmsn.com - March 13 at 6:33 PMZinc Polycarboxylate Cement Market Size is Anticipated to Reach USD 282.1 million by 2031, with a CAGR of 5.6%. - Transparency Market Research, Inc.finance.yahoo.com - March 13 at 1:33 PMAllogene, Arbor Announce Global Gene Editing Licensing Agreement For CAR T Platformmarkets.businessinsider.com - March 12 at 10:16 AMAllogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Diseaseglobenewswire.com - March 12 at 8:30 AMANTION BIOSCIENCES SA: Antion Biosciences announces latest data and validation of its technology platform through important milestone achievementsfinanznachrichten.de - March 6 at 7:48 PMAllogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Updateglobenewswire.com - March 5 at 8:30 AMCaxton Associates LP Has $1.52 Million Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)marketbeat.com - February 28 at 3:48 PMAllogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conferenceglobenewswire.com - February 28 at 8:30 AMPrimecap Management Co. CA Lowers Stock Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)marketbeat.com - February 26 at 8:56 AMALGS Apr 2024 2.500 callca.finance.yahoo.com - February 25 at 10:19 AMAllogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asiafinance.yahoo.com - February 16 at 8:59 AMAllogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asiaglobenewswire.com - February 16 at 8:30 AMBarclays PLC Boosts Stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO)marketbeat.com - February 14 at 4:36 AMAllogene Therapeutics, Inc. (NASDAQ:ALLO) Sees Significant Decline in Short Interestmarketbeat.com - February 13 at 8:41 AMQ1 2024 EPS Estimates for Allogene Therapeutics, Inc. (NASDAQ:ALLO) Lifted by Zacks Researchmarketbeat.com - February 8 at 7:30 AM Get Allogene Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. Email Address Gold Mania (Ad)Former Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite). See his free reveal right here. ALLO Media Mentions By Week ALLO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALLO News Sentiment▼0.480.58▲Average Medical News Sentiment ALLO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALLO Articles This Week▼83▲ALLO Articles Average Week Get Allogene Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PROK News Today HUMA News Today TSHA News Today ALEC News Today FATE News Today CABA News Today CCCC News Today EDIT News Today VYGR News Today VALN News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALLO) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICElon to Transform U.S. Economy? Porter & CompanyMissed NVDA? Buy this AI stock NOWChaikin AnalyticsShocking: One AI startup's revenue could surge 4,735%Manward PressGlobal crypto currency reset (41 major banks signed up)Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
